High-purity Semax nasal spray for sale provides laboratories with a standardized, stable liquid research reagent derived from the heptapeptide ACTH(4-10) fragment. Formulated specifically for controlled intranasal administration in preclinical models, PX1 Research supplies analytical-grade Semax backed by lot-specific third-party COAs, RP-HPLC purity testing, and quantitative mass spectrometry.
High-purity Semax nasal spray for sale provides laboratories with a standardized, stable liquid research reagent derived from the heptapeptide ACTH(4-10) fragment. Formulated specifically for controlled intranasal administration in preclinical models, PX1 Research supplies analytical-grade Semax backed by lot-specific third-party COAs, RP-HPLC purity testing, and quantitative mass spectrometry.
Semax nasal spray for sale through PX1 Research is a specialized, ready-to-use liquid solution containing the synthetic heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro (a modified ACTH(4-10) fragment). It is synthesized in ISO 17025 accredited, GMP-compliant facilities within the United States strictly for laboratory research use, providing high-purity experimental material (>99% RP-HPLC purity) designed for neurotrophic, neuroprotective, and gene-expression studies in animal and cell models.
Researchers seeking semax nasal spray for sale require exact molecular consistency, precise concentration metering, and complete absence of bacterial endotoxins. Preclinical protocols rely on liquid intranasal formulations to evaluate brain-derived neurotrophic factor (BDNF) upregulation and vascular responses without the confounding stress of invasive parenteral administration. PX1 Research ensures every batch undergoes rigorous analytical testing to meet institutional scientific requirements.
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic analog of human adrenocorticotropic hormone, specifically derived from the ACTH(4-10) sequence with a C-terminal tripeptide Pro-Gly-Pro (PGP) addition. This structural modification was designed to dramatically increase the peptide's resistance to enzymatic degradation by serum proteases and carboxypeptidases, extending its metabolic half-life in physiological solutions compared to native melanocortin fragments.
Unlike intact ACTH, Semax lacks hormonal adrenocorticotropic activity, meaning it does not trigger systemic steroidogenesis or activate adrenal corticosteroid release in test models. Instead, its primary actions are focused entirely on central regulatory cascades. When acquiring reagents via our all peptides catalog, researchers receive a peptide engineered for high chemical stability in aqueous solutions, making it ideal for non-invasive mucosal administration studies.
The primary focus of empirical investigation into Semax involves its modulation of neurotrophic factors, specifically Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF). Preclinical rodent models demonstrate that administration of Semax rapidly increases BDNF mRNA expression and protein levels within the hippocampus and basal forebrain regions. This rapid upregulation engages downstream Tropomyosin receptor kinase B (TrkB) receptor signaling cascades.
In vitro cellular assays reveal that activation of the BDNF/TrkB axis by Semax enhances neuronal survival, promotes dendritic arborization, and stimulates synaptogenesis under controlled experimental conditions. Researchers interested in neuroplasticity pathways frequently cross-reference these findings with broader research peptides targeting central nervous system repair and metabolic signaling, confirming that Semax acts as a potent positive regulator of intrinsic neurotrophic tone.
Beyond BDNF expression, animal models of transient middle cerebral artery occlusion (tMCAO) indicate that Semax exerts pronounced cellular protective effects during acute metabolic stress and hypoxia. In vivo gene expression profiling demonstrates that Semax administration influences over 100 genes related to immune response, vascular tone, and extracellular matrix remodeling within 24 hours of ischemic onset.
Specifically, preclinical data show that Semax suppresses inflammatory cytokine transcription (including IL-1β, IL-6, and TNF-α) while upregulating trophic support factors and microvascular growth elements. These cellular responses help maintain blood-brain barrier integrity and reduce peri-infarct neuronal loss in stroke and hypoxic brain injury models, rendering it a foundational molecule in cerebrovascular research.
When designing neurobiological experiments, investigators frequently evaluate Semax alongside other synthetic regulatory peptides to map distinct receptor mechanisms and physiological outcomes. A prominent point of comparison is Selank nasal spray, a synthetic heptapeptide derived from human tuftsin (Thr-Lys-Pro-Arg-Pro-Gly-Pro). While Semax acts primarily on the ACTH/melanocortin system and BDNF expression to influence neuroplasticity and executive pathways, Selank modulates GABAergic neurotransmission and enkephalin stability to alter stress response pathways.
In addition, researchers often compare basic Semax with modified variants like N-Acetyl Semax Amidate or other synthetic nootropics such as Noopept and Cerebrolysin fractions. The acetylated and amidated variants exhibit altered lipophilicity and resistance to aminopeptidase breakdown, yielding different pharmacokinetic curves in tissue distribution models. Choosing between standard Semax nasal spray and modified analogs depends on the required tissue penetration, receptor binding kinetics, and enzymatic stability demanded by the experimental model.
The liquid intranasal format of Semax offers significant technical advantages for laboratory protocols targeting the central nervous system. The nasal mucosa provides a direct olfactory and trigeminal pathway to the brain parenchyma, bypassing the blood-brain barrier (BBB) and avoiding hepatic first-pass metabolism. This allows researchers to study central biological effects at lower overall molar concentrations compared to systemic intraperitoneal or intravenous routes.
PX1 Research's pre-formulated nasal spray reagent is compounded using high-purity sterile water and buffered solutions designed to maintain osmotic balance and chemical stability. Pre-mixed liquid solutions eliminate laboratory reconstitution errors and minimize peptide aggregate formation, ensuring highly reproducible dosage volumetric metering across experimental cohorts.
Sourcing reliable research peptides requires strict analytical verification to prevent experimental invalidation caused by impurities, structural isomerism, or bacterial contamination. PX1 Research mandates third-party laboratory verification for every single lot of Semax nasal spray produced. Every certificate of analysis (COA) provides transparent proof of analytical identity and purity.
Quality parameters required for rigorous lab research include:
- Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) demonstrating absolute peptide purity ≥99.0%.
- Electrospray Ionization Mass Spectrometry (ESI-MS) confirming exact molecular weight (810.9 g/mol) and structural sequence integrity.
- Chromogenic LAL Endotoxin Testing ensuring bacterial endotoxins remain strictly below 0.5 EU/mg.
- ISO 17025 accredited analytical facility testing with complete lot traceability.
By enforcing these verification standards, PX1 Research provides institutional buyers, university researchers, and private laboratories with fully documented reagents optimized for reproducible scientific inquiry. For institutional pricing or bulk research requirements, qualified facilities can access our wholesale lab access platform.
To preserve peptide integrity and prevent degradation of the ACTH(4-10) sequence, liquid Semax nasal spray formulations must be stored under controlled thermal conditions upon delivery. Upon receipt from PX1 Research, unopened liquid containers should be refrigerated immediately at 2°C to 8°C for short-to-medium-term stability, or stored according to protocol requirements.
Avoid exposing liquid peptide solutions to direct ultraviolet light, high temperatures, or repeated physical agitation, which can induce physical shear stress and lead to peptide aggregation. When handling reagents inside laminar flow hoods or cleanroom environments, standard aseptic techniques must be observed to prevent cross-contamination. Detailed technical specifications and handling instructions are available within our institutional research library hub.
What is the primary target sequence of Semax?
Semax is an analog of the ACTH(4-10) fragment (Met-Glu-His-Phe) coupled with a C-terminal Pro-Gly-Pro tripeptide sequence that enhances stability against enzymatic degradation.
How does Semax nasal spray differ from lyophilized Semax powder?
Semax nasal spray is pre-dissolved in a sterile, micro-metered liquid buffer designed for direct mucosal research protocols, whereas lyophilized powder requires precise reconstitution in sterile water or bacteriostatic saline prior to administration.
What purity levels are guaranteed for Semax from PX1 Research?
PX1 Research guarantees a minimum of 99.0% purity verified by lot-specific Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and Electrospray Ionization Mass Spectrometry (ESI-MS).
Are PX1 Research peptides tested for bacterial endotoxins?
Yes. Every lot undergoes quantitative LAL assay testing to confirm endotoxin levels are maintained below 0.5 EU/mg, protecting cellular and animal models from inflammatory interference.
What is the recommended storage temperature for liquid Semax nasal spray?
Liquid Semax nasal spray solutions should be stored under refrigeration at 2°C to 8°C to ensure chemical stability and prevent enzymatic breakdown or degradation over time.
How does Semax compare to Selank in preclinical literature?
Preclinical studies show Semax primary targets neurotrophic expression (BDNF/NGF) and ischemic tissue responses, whereas Selank primarily acts on GABAergic modulation and enkephalin breakdown degradation pathways.
Can Semax nasal spray be purchased for personal or clinical use?
No. Semax nasal spray is supplied strictly for laboratory research, analytical testing, and in vitro or preclinical animal experiments. Human administration or medical use is strictly prohibited.
Where are PX1 Research peptides manufactured and shipped from?
All PX1 Research compounds are manufactured in US-based, GMP-compliant facilities and shipped directly from distribution centers located in California and Arizona, with same-day shipping on orders placed Monday through Friday.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.